The most common cause of glaucoma surgery failure is scar formation induced by activation of wound-healing responses and resultant fibrosis at the surgical site. We investigated the effects of ripasudil, a Rho kinase inhibitor, on activation of human conjunctival fibroblasts (HConF). HConF were pretreated with different concentrations of ripasudil for 1 h before addition of transforming growth factor (TGF)-β2, followed by incubation for 48 h. TGF-β2-treated fibroblasts exhibited a significant increase in expression of α-smooth muscle actin (α-SMA), a marker of fibroblast-to-myofibroblast differentiation, and this increase was significantly suppressed, in a dose-dependent manner, by pretreatment with ripasudil. Ripasudil pretreatment also significantly attenuated TGF-β2-induced fibronectin production and collagen gel contraction. TGF-β2 increased both the number of viable cells and the number of cells in the G2/M phase of the cell cycle; these effects were attenuated by pretreatment with ripasudil. In addition, we explored the effects of ripasudil on stimulation of HConF by activated macrophages. Human monocytic cell line THP-1 cells were differentiated into M1 or M2 macrophage-like cells, and HConF were treated with conditioned media derived from these macrophages in the presence or absence of ripasudil. Conditioned medium from M2 macrophage-like cells induced a significant increase in α-SMA expression, viable cell numbers, and gel contraction, all of which were significantly suppressed by ripasudil. Thus, overall, ripasudil attenuated activation of human conjunctival fibroblasts. Ripasudil may be of therapeutic utility, preventing excessive scarring after glaucoma filtration surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.exer.2016.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RHO-Associated Coiled-Coil-Containing Protein Kinase Inhibitors Significantly Modulate the Epithelial-Mesenchymal Transition Induced by TGF-β2 in the 2-D and 3-D Cultures of Human Corneal Stroma Fibroblasts.
Biomedicines
December 2024
Department of Ophthalmology, School of Medicine, Sapporo Medical University, S1 W16 Chuo-ku, Sapporo City 060-8543, Hokkaido, Japan.
Background/objectives: The objective of the present study was to examine the unidentified effects that RHO-associated coiled-coil-containing protein kinase 1 and 2 antagonists exert on the transforming growth factor beta2-induced epithelial-mesenchymal transition of the human corneal stroma.
Methods: In the presence or absence of pan-RHO-associated coiled-coil-containing protein kinase inhibitors, ripasudil or Y27632 and RHO-associated coiled-coil-containing protein kinase 2 inhibitor, KD025, we analyzed the following: (1) planar proliferation caused by trans-endothelial electrical resistance and the cellular metabolic characteristics of the two-dimensional cultures of human corneal stroma fibroblasts; (2) the physical properties of a three-dimensional human corneal stroma fibroblasts spheroid; and (3) the gene expressions and their regulators in the extracellular matrix, along with the tissue inhibitors of metalloproteinases and matrix metalloproteinases and the endoplasmic reticulum stress-related factors of the two-dimensional and three-dimensional cultures in human corneal stroma fibroblasts.
Results: Exposure to 5 nM of the transforming growth factor beta2 markedly increased the trans-endothelial electrical resistance values as well as the metabolic function in two-dimensional cultures of human corneal stroma fibroblasts.
Late-Onset Ocular Hypotensive Effect of Ripasudil on Primary Open-Angle Glaucoma.
Clin Ophthalmol
December 2024
Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Purpose: We evaluated the late-onset ocular hypotensive effect of ripasudil after long-term administration in real-world clinical data and investigated its associated factors in primary open-angle glaucoma (POAG).
Patients And Methods: We reviewed the clinical patients with POAG who newly started ripasudil without changes of treatment. Enrolled eyes were assigned to two groups: positive group with the late-onset effect and negative group.
Ripasudil's paradox: bullous keratopathy with honeycomb twist.
BMJ Case Rep
December 2024
Ophthalmology, All India Institute of Medical Sciences, Nagpur, India.
We present a case of a male patient in his mid-50s who presented with bullous keratopathy secondary to an anterior chamber intraocular lens, complicated by superimposed honeycomb keratopathy while on ripasudil 0.4%. The bullous keratopathy was characterised by generalised microcystic epithelial oedema, alongside more centrally located, variable-sized macrocystic epithelial oedema with a honeycomb appearance.
View Article and Find Full Text PDFThe Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy.
Invest Ophthalmol Vis Sci
November 2024
Glaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Article Synopsis
- The study aimed to explore how topical 2% ripasudil (a Rho kinase inhibitor) protects the nervous system, specifically looking at retinal ganglion cell (RGC) loss in mice exposed to increased intraocular pressure (IOP) and optic nerve damage.
- Results showed that ripasudil significantly reduced RGC axon and soma loss compared to saline-treated controls, indicating its protective effects against nerve damage.
- The findings suggest that ripasudil works by suppressing ROCK signaling pathways in the retina and optic nerve, affecting both RGCs and astrocyte responses to elevated IOP.
Descemet Endothelial Thickness Comparison Trial II (DETECT II): multicentre, outcome assessor-masked, placebo-controlled trial comparing Descemet membrane endothelial keratoplasty (DMEK) to Descemet stripping only (DSO) with adjunctive ripasudil for Fuchs dystrophy.
BMJ Open Ophthalmol
October 2024
Ophthalmology, Stanford University, Stanford, California, USA
Article Synopsis
- The study compares the effectiveness of two surgical approaches—Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping only (DSO)—for treating Fuchs endothelial corneal dystrophy (FECD) in a clinical trial called DETECT II.
- A total of 60 patients will be randomly assigned to receive either DMEK with a placebo or DSO with a drug called ripasudil, and the main goal is to evaluate visual improvement after 12 months.
- The trial aims not only to assess visual outcomes but also to explore other factors like cost-effectiveness and the incidence of adverse events, with findings planned for dissemination in scientific publications and conferences.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!